INHBE and breast cancer: These data provide a possible novel direct anti-proliferative mechanism of action of ZOL on breast cancer cells involving activin signaling, that could contribute to the enhanced anti-tumour effects of the drug in neo-adjuvant clinical trials of patients with ER–ve breast cancer, and requires further research in clinical samples.